Functional mapping of protective domains and epitopes in the rotavirus VP6 protein

Journal of Virology

Volumn 74, Issue 24, 2000, Pages 11574-11580

  Choi, A H C ^a   Basu, M ^a   McNeal, M M ^a   Flint, J ^a   VanCott, J L ^a   Clements, J D ^a   Ward, R L ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CD1 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; EPITOPE; PROTEIN VP6; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CHIMERA; CONTROLLED STUDY; ESCHERICHIA COLI; GENETIC ENGINEERING; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; ROTAVIRUS; T LYMPHOCYTE; VIRUS IMMUNITY; VIRUS INFECTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, VIRAL; CAPSID; CAPSID PROTEINS; EPITOPE MAPPING; MICE; MOLECULAR SEQUENCE DATA; PEPTIDE MAPPING; ROTAVIRUS; VIRUS SHEDDING;

EID: 0034469711     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.24.11574-11580.2000     Document Type: Article

References (33)

1. Identification of a T-helper cell epitope on the rotavirus VP6 protein
2. The magnitude of the global problem of diarrhoeal disease: A ten-year update
3. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants
4. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group
5. A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding
6. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1
7. Immunogenicity of a contiguous T-B synthetic epitope of the A/PR/8/34 influenza virus
8. Withdrawal of rotavirus vaccine recommendation
9. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles
10. Particle bombardment-mediated DNA vaccination with rotavirus VP6 induces high levels of serum rotavirus IgG but fails to protect mice against challenge
11. Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein
12. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants
13. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase
14. HLA class II peptide binding specificity and autoimmunity
15. Alternate binding of actin and calmodulin to multiple sites on dystrophin
16. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru
17. Immunogenicity, safety and efficacy of tetravalent rhesushuman, reassortant rotavirus vaccine in Belem, Brazil
18. Antibody-dependent and -independent protection following intranasal immunization of mice with rotavirus particles
19. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
20. Universal influenza A vaccine based on the extracellular domain of the M2 protein
21. Chemistry of peptides associated with MHC class I and class II molecules
22. MHC ligands and peptide motifs: First listing
23. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - Report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group
24. A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population
25. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations
26. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide
27. Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice
28. Comparison of the rotavirus gene 6 from different species by sequence analysis and localization of subgroup-specific epitopes using site-directed mutagenesis
29. Clinical trials of live oral rotavirus vaccines: The Finnish experience
30. A peptide construct containing B-cell and T-cell epitopes from the foot-and-mouth disease viral VP1 protein induces efficient antiviral protection
31. Selective primary health care: An interim strategy for disease control in developing countries
32. Development of an adult mouse model for studies on protection against rotavirus